Jump to content

Cyproheptadine: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
No edit summary
Tags: Mobile edit Mobile web edit
No edit summary
Tags: Mobile edit Mobile web edit
Line 55: Line 55:
}}
}}
<!-- Definition and medical uses -->
<!-- Definition and medical uses -->
'''Cyproheptadine''', sold under the brand name '''Periactin''' among others, is a [[first-generation antihistamine]] in the tricyclic/tetracyclic class of antihistamines, which also includes [[promethazine]]. Cyproheptadine has a broad range of applications but is most commonly prescribed to relieve allergy related symptoms such as runny nose, itching eyes and hives. Cyproheptadine has [[antihistamine]], [[anticholinergic]], [[antiserotonergic]] and [[local anesthetic]] properties.
'''Cyproheptadine''', sold under the brand name '''Periactin''' among others is a [[first-generation antihistamine]] in the tricyclic/tetracyclic class of antihistamines, which also includes [[promethazine]]. Cyproheptadine has a broad range of applications but is most commonly prescribed to relieve allergy related symptoms such as runny nose, itching eyes and hives. Cyproheptadine has [[antihistamine]], [[anticholinergic]], [[antiserotonergic]] and [[local anesthetic]] properties.


<!-- Society and culture -->
<!-- Society and culture -->

Revision as of 03:20, 7 May 2019

Cyproheptadine
Clinical data
Pronunciation(/ˌsaɪproʊˈhɛptədiːn/[1]
Trade namesPeriactin, others
AHFS/Drugs.comMonograph
MedlinePlusa682541
License data
Pregnancy
category
  • AU: A
Routes of
administration		Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding96 to 99%
MetabolismHepatic.[3][4] Mostly CYP3A4 mediated.
Elimination half-life8.6 hours[2]
ExcretionFaecal (2-20%; 34% of this as unchanged drug) and renal (40%; none as unchanged drug)[3][4]
Identifiers
  • 4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.004.482 Edit this at Wikidata
Chemical and physical data
FormulaC21H21N
Molar mass287.398 g/mol g·mol−1
3D model (JSmol)
  • c43\C(=C1/CCN(C)CC1)c2ccccc2\C=C/c3cccc4
  • InChI=1S/C21H21N/c1-22-14-12-18(13-15-22)21-19-8-4-2-6-16(19)10-11-17-7-3-5-9-20(17)21/h2-11H,12-15H2,1H3 checkY
  • Key:JJCFRYNCJDLXIK-UHFFFAOYSA-N checkY
  (verify)

Cyproheptadine, sold under the brand name Periactin among others is a first-generation antihistamine in the tricyclic/tetracyclic class of antihistamines, which also includes promethazine. Cyproheptadine has a broad range of applications but is most commonly prescribed to relieve allergy related symptoms such as runny nose, itching eyes and hives. Cyproheptadine has antihistamine, anticholinergic, antiserotonergic and local anesthetic properties.

It was patented in 1959 and came into medical use in 1961.[5]

Medical uses

Periactin (cyproheptadine) 4 mg tablets
  • Cyproheptadine is used to treat allergic reactions (specifically hay fever).[6] The evidence for its use for this purpose in children is weak and ketotifen and loratadine showed equal or better results in the small trials in which they have been compared.[7]
  • It is sometimes used, especially in its liquid formulation, as a preventive measure against migraine in children and adolescents,[8] but as of 2017 the evidence for this was weak.[7][9] This use is on the label in the UK and some other countries.
  • It is also used off-label in the treatment of cyclical vomiting syndrome in infants; the only evidence for this use comes from retrospective studies.[10]
  • Cyproheptadine is sometimes used off-label to improve akathisia in people on antipsychotic medications.[11]
  • It used off-label to treat various dermatological conditions, including psychogenic itch[12] drug-induced hyperhidrosis (excessive sweating),[13] and prevention of blister formation for some people with epidermolysis bullosa simplex.[14]
  • One of the effects of the drug is increased appetite and weight gain, which has led to its use (off-label in the USA) for this purpose in children who are wasting as well as people with cystic fibrosis.[15][16] The evidence for the efficacy in light of other side effects is weak.[7][17]
  • It is sometimes used off-label in the management of moderate to severe cases of serotonin syndrome, a complex of symptoms associated with the use of serotonergic drugs, such as selective serotonin reuptake inhibitors and monoamine oxidase inhibitors), and in cases of high levels of serotonin in the blood resulting from a serotonin-producing carcinoid tumor.[18][19]
  • Ceproheptadine is a serotonin antagonist and antihistamine agent that has also been used off label to treat migraines, nightmares and behavioural abnormalities. It has even been used to treat sexual dysfunction cause by SSRIs. Its pharmacological action makes it an ideal agent to treat symptoms associated with increased serotonin concentrations.[20]

Adverse effects

Adverse effects include:[3][4]

  • Sedation and sleepiness (often transient)
  • Dizziness
  • Disturbed coordination
  • Confusion
  • Restlessness
  • Excitation
  • Nervousness
  • Tremor
  • Irritability
  • Insomnia
  • Paresthesias
  • Neuritis
  • Convulsions
  • Euphoria
  • Hallucinations
  • Hysteria
  • Faintness
  • Allergic manifestation of rash and edema
  • Diphoresis
  • Urticaria
  • Photosensitivity
  • Acute labyrinthitis
  • Diplopia (seeing double)
  • Vertigo
  • Tinnitus
  • Hypotension (low blood pressure)
  • Palpitation
  • Extrasystoles
  • Anaphylactic shock
  • Hemolytic anemia
  • Blood dyscrasias such as leukopenia, agranulocytosis and thrombocytopenia
  • Cholestasis
  • Hepatic (liver) side effects such as:
- Hepatitis
- Jaundice
- Hepatic failure[21]
- Hepatic function abnormality
- Blurred vision
- Constipation
- Xerostomia (dry mouth)
- Tachycardia (high heart rate)
- Urinary retention
- Difficulty passing urine
- Nasal congestion
- Nasal or throat dryness
  • Urinary frequency
  • Early menses
  • Thickening of bronchial secretions
  • Tightness of chest and wheezing
  • Fatigue
  • Chills
  • Headache
  • Increased appetite
  • Weight gain

Overdose

Gastric decontamination measures such as activated charcoal are sometimes recommended in cases of overdose. The symptoms are usually indicative of CNS depression (or conversely CNS stimulation in some) and excess anticholinergic side effects. The LD50 in mice is 123 mg/kg and 295 mg/kg in rats.[3][4]

Pharmacology

Pharmacodynamics

Cyproheptadine[22]
Site Ki (nM) Species Ref
H1 0.06 Human
H2 ND ND
H3 >10,000 Human
H4 202 Human
M1 12 Human
M2 7 Human
M3 12 Human
M4 8 Human
M5 11.8 Human
5-HT1A 59 Human
5-HT2A 1.67 Human
5-HT2B 1.54 Human
5-HT2C 2.23 Human
5-HT3 228 Mouse
5-HT6 142 Human
5-HT7 123 Human
D1 117 Human
D2 112 Human
D3 8 Human
SERTTooltip Serotonin transporter 4,100 Rat
NETTooltip Norepinephrine transporter 290 Rat
DATTooltip Dopamine transporter ND ND
Values are Ki (nM). The smaller the value,
the more strongly the drug binds to the site.

Cyproheptadine is a very potent antihistamine or antagonist of the H1 receptor. At higher concentrations, it also has anticholinergic, antiserotonergic, and antidopaminergic activities. Of the serotonin receptors, it is an especially potent antagonist of the 5-HT2 receptors, and this underlies its effectiveness in the treatment of serotonin syndrome.

Cyproheptadine is known to be an antagonist or inverse agonist of all of the receptors listed in the adjacent table.[22]

Cyproheptadine has been shown to be able to protect against bacterial endotoxin, histamine, cortisol, serotonin, estrogen, acetylcholine, growth hormone, beta-endorphin, as well as being able to prevent the synthesis from free fatty acids, of the prostaglandins.

Cyproheptadine has been used to promote the production of cholesterol and testosterone, and there is good reason to believe that by protecting against the stress and inflammation promoting substances and encouraging thyroid metabolism, it can (indirectly at least) assist in the production of some of the other protective anti-aging hormones, including pregnenolone, progesterone and DHEA.[23]

Pharmacokinetics

Cyproheptadine is well-absorbed following oral ingestion, with peak plasma levels occurring after 1 to 3 hours.[24] Its terminal half-life when taken orally is approximately 8 hours.[2]

Chemistry

Cyproheptadine is a tricyclic benzocycloheptene and is closely related to pizotifen and ketotifen as well as to tricyclic antidepressants.

Research

Cyproheptadine has been studied for the treatment of posttraumatic stress disorder.[25]

Veterinary use

Cyproheptadine is used in cats as an appetite stimulant[26] and as an adjunct in the treatment of asthma.[27] Possible adverse effects include excitement and aggressive behavior.[28] The elimination half-life of cyproheptadine in cats is 12 hours.[27]

Cyproheptadine is a second line treatment for pituitary pars intermedia dysfunction in horses.[29][30]

References

  1. ^ "Cyproheptadine". Dictionary.com Unabridged (Online). n.d.
  2. ^ a b Gunja N, Collins M, Graudins A (2004). "A comparison of the pharmacokinetics of oral and sublingual cyproheptadine". Journal of Toxicology. Clinical Toxicology. 42 (1): 79–83. doi:10.1081/clt-120028749. PMID 15083941.
  3. ^ a b c d "CYPROHEPTADINE HYDROCHLORIDE tablet [Boscogen, Inc.]" (PDF). DailyMed. Boscogen, Inc. November 2010. Retrieved 26 October 2013.
  4. ^ a b c d "PRODUCT INFORMATION PERIACTIN® (cyproheptadine hydrochloride)" (PDF). Aspen Pharmacare Australia. Aspen Pharmacare Australia Pty Ltd. 17 November 2011. Retrieved 26 October 2013.
  5. ^ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 547. ISBN 9783527607495.
  6. ^ MedlinePlus Drug Information: Cyproheptadine
  7. ^ a b c De Bruyne, P; Christiaens, T; Boussery, K; Mehuys, E; Van Winckel, M (January 2017). "Are antihistamines effective in children? A review of the evidence". Archives of Disease in Childhood. 102 (1): 56–60. doi:10.1136/archdischild-2015-310416. PMID 27335428.
  8. ^ Merison, K; Jacobs, H (November 2016). "Diagnosis and Treatment of Childhood Migraine". Current Treatment Options in Neurology. 18 (11): 48. doi:10.1007/s11940-016-0431-4. PMID 27704257.
  9. ^ Saito, Y; Yamanaka, G; Shimomura, H; Shiraishi, K; Nakazawa, T; Kato, F; Shimizu-Motohashi, Y; Sasaki, M; Maegaki, Y (May 2017). "Reconsideration of the diagnosis and treatment of childhood migraine: A practical review of clinical experiences". Brain & Development. 39 (5): 386–394. doi:10.1016/j.braindev.2016.11.011. PMID 27993427.
  10. ^ Salvatore, S; Barberi, S; Borrelli, O; Castellazzi, A; Di Mauro, D; Di Mauro, G; Doria, M; Francavilla, R; Landi, M; Martelli, A; Miniello, VL; Simeone, G; Verduci, E; Verga, C; Zanetti, MA; Staiano, A; SIPPS Working Group on, FGIDs. (16 July 2016). "Pharmacological interventions on early functional gastrointestinal disorders". Italian Journal of Pediatrics. 42 (1): 68. doi:10.1186/s13052-016-0272-5. PMC 4947301. PMID 27423188.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  11. ^ Taylor, David; Paton, Carol; Kapur, Shitij (2015). The Maudsley Prescribing Guidelines in Psychiatry. John Wiley & Sons. p. 85. ISBN 9781118754573.
  12. ^ Szepietowski, JC; Reszke, R (2016). Psychogenic Itch Management. Vol. 50. pp. 124–32. doi:10.1159/000446055. ISBN 978-3-318-05888-8. PMID 27578081. {{cite book}}: |journal= ignored (help)
  13. ^ Ashton AK, Weinstein WL (May 2002). "Cyproheptadine for drug-induced sweating". American Journal of Psychiatry. 159 (5): 874–5. doi:10.1176/appi.ajp.159.5.874-a. PMID 11986151.
  14. ^ Pfendner, Ellen G.; Bruckner, Anna L. (October 13, 2016). "Epidermolysis Bullosa Simplex". GeneReviews. PMID 20301543.
  15. ^ Ciproheptadina, estimulante del apetito (Cyproheptadine, appetite stimulant)
  16. ^ Bioplex NF
  17. ^ Chinuck, R; Dewar, J; Baldwin, DR; Hendron, E (27 July 2014). "Appetite stimulants for people with cystic fibrosis". The Cochrane Database of Systematic Reviews (7): CD008190. doi:10.1002/14651858.CD008190.pub2. PMID 25064192.
  18. ^ Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3.
  19. ^ Iqbal, MM; Basil, MJ; Kaplan, J; Iqbal, MT (November 2012). "Overview of serotonin syndrome". Annals of Clinical Psychiatry. 24 (4): 310–8. PMID 23145389.
  20. ^ Cite error: The named reference https://cowseatgrass.org/2018/07/02feeling-very-periactin was invoked but never defined (see the help page).
  21. ^ Chertoff, Jason (8 July 2014). "Cyproheptadine-Induced Acute Liver Failure". ACG Case Reports Journal. 1 (4): 212–213. doi:10.14309/crj.2014.56. PMC 4286888. PMID 25580444.
  22. ^ a b Roth, BL; Driscol, J. "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 14 August 2017.
  23. ^ Cite error: The named reference https://cowseatgrass.org/2018/07/02/feeling-very-periactin was invoked but never defined (see the help page).
  24. ^ Lindsay Murray; Frank Daly; David McCoubrie; Mike Cadogan (15 January 2011). Toxicology Handbook. Elsevier Australia. p. 388. ISBN 978-0-7295-3939-5. Retrieved 27 November 2011.
  25. ^ Dabaghzadeh, F; Khalili, H; Ghaeli, P; Dashti-Khavidaki, S (December 2012). "Potential benefits of cyproheptadine in HIV-positive patients under treatment with antiretroviral drugs including efavirenz". Expert Opinion on Pharmacotherapy. 13 (18): 2613–24. doi:10.1517/14656566.2012.742887. PMID 23140169.
  26. ^ Agnew, W; Korman, R (September 2014). "Pharmacological appetite stimulation: rational choices in the inappetent cat". Journal of Feline Medicine and Surgery. 16 (9): 749–56. doi:10.1177/1098612X14545273. PMID 25146662.
  27. ^ a b Dowling PM (February 8, 2005). "Systemic Therapy of Airway Disease: Cyproheptadine". In Kahn CM, Line S, Aiello SE (eds.). The Merck Veterinary Manual (9th ed.). John Wiley & Sons. ISBN 978-0-911910-50-6. {{cite book}}: External link in |chapterurl= (help); Unknown parameter |chapterurl= ignored (|chapter-url= suggested) (help) Retrieved on October 26, 2008.
  28. ^ Dowling PM (February 8, 2005). "Drugs Affecting Appetite". In Kahn CM, Line S, Aiello SE (eds.). The Merck Veterinary Manual (9th ed.). John Wiley & Sons. ISBN 978-0-911910-50-6. {{cite book}}: External link in |chapterurl= (help); Unknown parameter |chapterurl= ignored (|chapter-url= suggested) (help) Retrieved on October 26, 2008.
  29. ^ Durham, AE (April 2017). "Therapeutics for Equine Endocrine Disorders". The Veterinary Clinics of North America. Equine Practice. 33 (1): 127–139. doi:10.1016/j.cveq.2016.11.003. PMID 28190613.
  30. ^ Merck Vet Manual. "Hirsutism Associated with Adenomas of the Pars Intermedia". Retrieved April 24, 2011.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Cyproheptadine&oldid=895886377"